bluebird bio, Inc. (BLE.SG)
- Business Wire
bluebird bio Announces Receipt of Expected Notice from Nasdaq
SOMERVILLE, Mass., April 26, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports wi
- Business Wire
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOMERVILLE, Mass., April 11, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units ("RSUs") to twelve newly hired employees with a grant date of April 9, 2024 (the "Inducement Grants"). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2021 Inducement Plan.
- Business Wire
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
SOMERVILLE, Mass., March 26, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported fourth quarter and annual financial results and business highlights for the year ended December 31, 2023, including recent commercial and operational progress.
